Company Filing History:
Years Active: 2016
Title: Shuling Zheng: Innovator in BTK Inhibitors
Introduction
Shuling Zheng is a prominent inventor based in Shanghai, China. She has made significant contributions to the field of pharmaceuticals, particularly in the development of Bruton's Tyrosine Kinase (Btk) inhibitors. Her work is crucial for advancing therapies for Btk-mediated disorders.
Latest Patents
Shuling Zheng holds a patent for Btk inhibitors, which provides compounds according to a specific formula or pharmaceutically acceptable salts. This invention focuses on the use of Btk inhibitor compounds in therapeutic applications, particularly for treating disorders mediated by Btk. The patent highlights the potential of these compounds in improving patient outcomes.
Career Highlights
Zheng is currently employed at Merck Sharp & Dohme Corporation, where she continues to innovate in the pharmaceutical industry. Her expertise in Btk inhibitors positions her as a key player in the development of new treatments.
Collaborations
Throughout her career, Shuling Zheng has collaborated with notable colleagues, including Ronald M Kim and Jian Liu. These partnerships enhance her research and contribute to the advancement of therapeutic solutions.
Conclusion
Shuling Zheng's work in developing Btk inhibitors represents a significant advancement in the treatment of Btk-mediated disorders. Her contributions to the pharmaceutical field are invaluable and continue to impact patient care positively.